Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2007
10/02/2007US7276510 Viricides; prevent reproduction of human T-Cell lymphocyte virus
10/02/2007US7276509 Substance P; 2-(phenyl)-4-(3-oxo-piperazin-1-yl-)-piperidine-1-carboxylic acid; benzyl-methylamide; antagonists of the NK1 receptor; antidepressant, antiolytic; antiemetic
10/02/2007US7276508 Indole derivatives useful for the treatment of CNS disorders
10/02/2007US7276507 Pyridopyrazines and the use thereof as kinase inhibitors
10/02/2007US7276506 2-amino-4-ethoxy-6-(4-methoxyphenyl)-pteridine for example; treating transplant rejection, certain inflammatory diseases, cardiovascular disorders, nervous system disorders and cell proliferative disorders
10/02/2007US7276505 Immunomodulating heterocyclic compounds
10/02/2007US7276504 Nasally administering an imidazotriazinone substituted with an (alkoxy)(aminosulfonyl)phenyl group for treating diseases including psoriasis, female infertility, diabetes, glaucoma, cystic fibrosis, pre-eclampsia, Parkinsonism, tinnitus, pain, gastric motility disorders, and pulmonary hypertension
10/02/2007US7276503 Administration of optically pure (S,S) reboxetine, or a salt thereof; diminished adverse side effects
10/02/2007US7276502 For therapy and prophylaxis of immunodeficiency disorders, inflammatory diseases, allergic diseases, autoimmune diseases, proliferative disorders, immunologically-mediated diseases, or respiratory disorders
10/02/2007US7276501 6-(4-substituted-anilino)pyrimidine derivatives, method for preparation thereof and antiviral pharmaceutical composition comprising the same
10/02/2007US7276500 Substituted amides, their preparation and use
10/02/2007US7276499 Sulfur-containing taxanes, specially covalently bonded to a cell binding agent for targeted delivey to specific cell populations
10/02/2007US7276498 E.g., 9,27-dihydroxy-3-{2-[4-hydroxy-3-methoxycyclohexyl]-1-methylethyl}-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-37-phenyl 4,9,10,12,13,14,15,18,21,22,23,24,25,26,27,32,33,34,34a-nonadecahydro-3H-23,27-epoxy-18,15-(epoxyimino)pyrido[2,1-c][1,4]oxazacyclohentriacontine-1,5,11,28,29(6H,31H)-pentone
10/02/2007US7276497 Cytotoxic agents comprising new maytansinoids
10/02/2007US7276496 Cyclic malonamides as inhibitors of Aβ protein protection
10/02/2007US7276495 Substituted lactams as inhibitors of Aβ protein production
10/02/2007US7276494 Photodynamic therapy; anticancer agents, vision defects, autoimmune disease, restenosis, skin disorders; cancer vaccine; medical diagnosis
10/02/2007US7276493 Hydroxy substituted cyclic amide; use in controlling Rhizoctinia solani, Pythium aphanidermatum, Botrytis cinerea in plants
10/02/2007US7276492 Use of ACE inhibitors for treatment of patients suffering from behavioral disorders
10/02/2007US7276491 Administerng urea derivatives such as1-(3-Cyano-phenyl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)-naphthalen-1-yl]-urea for therapy of disease or condition relating to blood coagulation or fibrinolysis
10/02/2007US7276489 At least two oligonucleotides linked at their 3' ends, internucleoside linkages or functionalized nucleobase or sugar to a nonnucleotidic linker, at least one oligonucleotide an immunostimulant having accessible 5' end
10/02/2007US7276487 9a, 11-3C-bicyclic 9a-azalide derivatives
10/02/2007US7276486 Compositions for vaginal treatment
10/02/2007US7276485 Flowable nondigestible oil and process for making
10/02/2007US7276468 Neutralizes the adverse health effects of both chemical and biological compounds, especially chemical warfare (CW) and biological warfare (BW) agents
10/02/2007US7276364 Nucleic acids encoding endotheliases, endotheliases and uses thereof
10/02/2007US7276359 Polynucleotide composition, method of preparation, and use thereof
10/02/2007US7276348 Using benzodiazepine derivatives to treat and prevent defects in programed cell death, autoimmune, inflammatory and cell proliferative diseases
10/02/2007US7276258 Herbal extract and compound lupinoside and its analogues as anti-diabetic type II drugs from plant Pueraria tuberosa
10/02/2007US7276253 Use of an oral dosage with quick release and storage stability: core of omeprazole, lansoprazole or pantoprazole and adjuvants; an intermediate layer having a gastric juice-resistant partially alkali neutralized polymer with cation exchange capacity, and an outer gastric juice resistant layer
10/02/2007US7276252 Material handling of toxic drugs; multilayer forms
10/02/2007US7276250 Sustained release formulations of oxymorphone
10/02/2007US7276249 Phospholipid-free, having a D50 particle size of less than 500 nm, andhaving a surface stabilizer; improved pharmacokinetic profiles and reduced fed/fasted variability
10/02/2007US7276248 Conjugate having a cleavable linkage for use in a liposome
10/02/2007US7276243 Nucleic acid having a sequence that is codon-optimized for high level expression in a yeast cell; proteins produced provide effective immunoprophylaxis against papillomavirus infection through neutralizing antibody and cell-mediated immunity
10/02/2007US7276242 Fowl pox viral construct composed of a first nucleic acid molecule encoding HIV Gag and/or Pol or derivatives and a second nucleic acid molecule encoding gamma-interferon and derivatives, effective in inducing, enhancing or otherwise stimulating an immune response to Gag and/or Pol.
10/02/2007US7276233 Methods of treating neoplasia with combinations of target cell-specific adenovirus and chemotherapy
10/02/2007US7276228 Methods for treating hematological disorders through inhibition of DNA methylation and histone deacetylase
10/02/2007US7276050 Trans-scleral drug delivery method and apparatus
10/02/2007CA2413424C Substituted bicyclic derivatives for the treatment of abnormal cell growth
10/02/2007CA2412564C Purine derivatives
10/02/2007CA2401229C Aryl fused azapolycyclic compounds
10/02/2007CA2387357C Derivatives of pyrazolo[4,3-d]pyrimidin-7-ones which inhibit cyclic guanosine 3',5'-monophosphate phosphodiesterase
10/02/2007CA2378613C Selective iglur5 receptor antagonists for the treatment of migraine
10/02/2007CA2378369C Small molecules useful in the treatment of inflammatory disease
10/02/2007CA2349013C Intermediate for the synthesis of amlodipine, a process for the preparation thereof and corresponding use
10/02/2007CA2330756C Indole derivatives and their use for the treatment of malignant and other diseases based on pathological cell proliferation
10/02/2007CA2309027C Method for treating hypercholesterolemia with unsubstituted polydiallylamine
10/02/2007CA2298033C Certain 5-alkyl-2-arylaminophenylacetic acids and derivatives
10/02/2007CA2296653C Treatment of diabetes with thiazolidinedione, insulin secretagogue and biguanide
10/02/2007CA2290537C Use of taurolidine for treatment of leukemias
10/02/2007CA2289509C Novel compounds
10/02/2007CA2262421C Substituted pyrrolopyrimidines and processes for their preparation
10/02/2007CA2261887C Covalent polar lipid conjugates with biologically-active compounds for use in salves
10/02/2007CA2251114C Treatment of arthritis disorders, rheumatoid arthritis and manifestations associated with rheumatoid disorders
10/02/2007CA2203417C Bisarylcarbinol derivatives as inhibitors of leukotriene biosynthesis
10/02/2007CA2184049C Thermally stable storable crystalline modification of n-methyl-n-[(1s)-1-phenyl-2-((3s)-3-hydroxy-pyrrolidin-1-yl)ethyl]-2,2-diphenylacetamide and a process for its preparation
10/02/2007CA2176376C Use of 2-amino purine derivatives for the treatment and prophylaxis of human herpes virus 6 infections
10/02/2007CA2096407C Retroviral protease inhibitors
10/02/2007CA2027341C Process for the preparation of 3-(l-pyroglutamyl)-l-thiazolidine-4-carboxylic acid and its derivatives
09/2007
09/30/2007CA2541561A1 Predicting negative symptom improvement during clozapine treatment
09/28/2007CA2582027A1 A pharmaceutical composition for the treatment of pathologies caused by the general response of the immune system
09/27/2007WO2007109813A1 Imidazoquinoxaline compounds as immunomodulators
09/27/2007WO2007109812A2 Immunopotentiating compounds
09/27/2007WO2007109783A2 Substituted pyrimidine kinase inhibitors
09/27/2007WO2007109735A2 A nonleachable composition and method to use
09/27/2007WO2007109731A2 Healing powder and method of use thereof
09/27/2007WO2007109698A2 Novel formulations
09/27/2007WO2007109661A2 Methods of preparation and resolution of e/z isomers of vinylfuro[2,3-d] pyrimidine and their biological activities
09/27/2007WO2007109633A2 Organotellurium and selenium-based antimicrobial antimicrobial formulations and articles
09/27/2007WO2007109615A2 β -LACTAMYL VASOPRESSIN V2 ANTAGONISTS
09/27/2007WO2007109585A2 Bisphosphonate compounds and methods
09/27/2007WO2007109577A1 Alkylamine-substituted bicyclic aryl compounds useful as modulators of ppar
09/27/2007WO2007109561A1 Immunomodulatory saccharide compounds
09/27/2007WO2007109530A1 Cyclosporin a compositions
09/27/2007WO2007109459A2 Pyridines and pyridine n-oxides as modulators of thrombin
09/27/2007WO2007109434A1 Besylate salt form of 1- (5-tert-butyl-2-p-t0lyl-2h-pyraz0l-3-yl) -3- (4- (6- (morpholin-4-yl-methyl) -pyrid in- 3 -yl) -naphthalen- 1-yl) -urea and polymorphs thereof
09/27/2007WO2007109363A2 Methods and compositions for inhibiting impdh isoform 1
09/27/2007WO2007109362A2 Benzoimidazolyl-parazine compounds for inflammation and immune-related uses
09/27/2007WO2007109357A2 Controlled release formulation of tolterodine
09/27/2007WO2007109355A2 6,7,8, 9 -tetrahydro- 5h- pyrimido [4, 5-d] azepin-4-yl] -amine derivatives as modulators of trpvl for the treatment of pain
09/27/2007WO2007109330A2 S1p receptor modulating compounds
09/27/2007WO2007109312A2 Disease modifying anti-arthritic activity of 2-methoxyestradiol
09/27/2007WO2007109290A2 Water-soluble zinc ionophores, zinc chelators, and/or zinc complexes and use for treating cancer
09/27/2007WO2007109289A1 Enantiomerically pure s-etifoxine, pharmaceutical compositions thereof and methods of their use
09/27/2007WO2007109288A2 Enantiomerically pure r-etifoxine, pharmaceutical compositions thereof and methods of their use
09/27/2007WO2007109275A2 Paclitaxel combination
09/27/2007WO2007109248A2 Treatment or prevention of scarring, capsular contractures and/or hyperpigmentation using leukotriene receptor antagonist and vitamin e
09/27/2007WO2007109247A2 Flexible, compressed intravaginal rings, methods of making and using the same, and apparatus for making the same
09/27/2007WO2007109244A2 Novel nanoparticles for delivery of active agents
09/27/2007WO2007109238A1 Heterocyclic substituted pyridine compounds with cxcr3 antagonist activity
09/27/2007WO2007109230A2 Nutrient compositions for the treatment and prevention of inflammation and disorders associated therewith
09/27/2007WO2007109217A2 Compounds from an extract of artemisia and methods for treating disorders
09/27/2007WO2007109201A2 Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
09/27/2007WO2007109192A2 Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
09/27/2007WO2007109184A2 Anti-cancer activity augmentation compounds and formulations and methods of use thereof
09/27/2007WO2007109180A2 Stabilized, sterilized collagen scaffolds with active adjuncts attached
09/27/2007WO2007109178A2 Indole derivatives as inhibitors of histone deacetylase
09/27/2007WO2007109175A1 N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors
09/27/2007WO2007109174A2 Compositions and methods for modulation of mcl-1 expression
1 ... 3563 3564 3565 3566 3567 3568 3569 3570 3571 3572 3573 3574 3575 3576 3577 3578 3579 3580 3581 3582 3583 ... 7860